MiRNA Regulation of MIF in SLE and Attenuation of Murine Lupus Nephritis With miR-654

Objective: Macrophage Migration Inhibitory Factor (MIF) is involved in the pathogenesis of systemic lupus erythematosus (SLE) and lupus nephritis (LN). MicroRNAs (miRNAs) play important roles in LN but whether specific miRNAs regulate the expression of MIF in LN is unknown. We explore specific miRNAs that can regulate MIF expression, and investigate miR-654 for the treatment of experimentally-induced murine lupus nephritis.Methods: Sera samples from 24 SLE patients and 24 controls were collected to measure the MIF concentration and its correlation with disease activity. A luciferase reporter assay was used to explore the target of miR-654. ELISA was used to detect the downstream cytokines regulated by miR-654 and MIF. Western blot was applied to measure the impact of miR-654 inhibition on downstream MIF signaling. The therapeutic efficacy of miR-654 was tested in the pristine-induced lupus mouse model. We further measured miR-654 expression and analyzed its relationship with MIF expression in SLE patients.Results: The serum MIF level was increased in SLE patients (p
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research

Related Links:

In conclusion, TNF-α − 863A allele (rs1800630) polymorphism is associated with increased risk of nephritis in South Indian SLE patients. We also found an interaction between HLA-DRB1*07 allele with TNF-α − 863 C/A promoter polymorphism giving supportive evidence for the tig ht linkage disequilibrium between TNF-α promoter SNPs and MHC class II DRB1 alleles.
Source: Indian Journal of Clinical Biochemistry - Category: Biochemistry Source Type: research
Conditions:   Lupus Erythematosus;   Lupus Nephritis Interventions:   Drug: Itolizumab [Bmab 600];   Drug: EQ001 Placebo Sponsors:   Equillium;   Biocon Limited Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
AbstractA Euro-Lupus regimen of low-dose intravenous cyclophosphamide (CFA) is commonly used to treat severe organ manifestations of systemic lupus erythematosus (SLE), particularly lupus nephritis (LN). There are no data on the distributions and dynamics of immune cell populations in patients with various treatment outcomes. The circulating immune cells of 11 female SLE patients were assessed before and after Euro-Lupus regimen (cumulative dose of 3000  mg CFA) by flow cytometry together with those of 16 healthy women. A subanalysis was performed in LN patients who achieved complete remission(CR;n  =  3...
Source: Archivum Immunologiae et Therapiae Experimentalis - Category: Allergy & Immunology Source Type: research
We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Tuesday, 12 November 2019, highlighting Roche data in lupus nephritis presented at the American Society of Nephrology (7 - 10 Nov) as well as the American College of Rheumatology Annual Meetings (8 - 13 Nov) in Washington, DC and Atlanta, United States, respectively.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
AbstractA false-positive result of syphilis screening test (FPST) is a characteristic finding in patients with systemic lupus erythematosus (SLE). We evaluated the clinical characteristics of SLE patients with FPST at SLE diagnosis. We reviewed the medical records of patients with SLE who underwent the Venereal Disease Research Laboratory or Rapid Plasma Reagin tests at SLE diagnosis at Severance Hospital between 2006 and 2016. The baseline characteristics and clinical outcomes were compared between patients with FPST and those with a negative result of syphilis screening test. Of 145 patients with SLE, 20 patients showed ...
Source: Rheumatology International - Category: Rheumatology Source Type: research
AbstractA 35 ‐year‐old African American male with a history of seizures, presented with nausea, vomiting, abdominal pain, thrombocytopenia (platelet count of 48,000) and acute renal failure (BUN/creatinine – 30/5.6). Urinalysis showed mild proteinuria and microscopic hematuria. He was diagnosed with syste mic lupus erythematosus (SLE) on the basis of positive ANA, anti‐dsDNA, arthritis, thrombocytopenia and hypocomplementemia fulfilling 5 of 11 SLE criteria (1). He also was positive for antibodies to cardiolipin, beta2‐glycoprotein‐I and lupus anticoagulant. ADAMTS13 level was lower than norma l b...
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: CLINICAL IMAGE Source Type: research
Hydroxychloroquine (HCQ, Plaquenil ®) is an antimalarial agent with immunosuppressive and cytotoxic properties that is considered safe and effective in pregnant patients with a history of mild lupus nephritis (LN).1-2 Hypersensitivity to hydroxychloroquine usually manifests as maculopapular exanthems within two to 33 days and rarely as eosinophilia or other systemic symptoms.3 Several prolonged desensitization protocols, ranging from four to 36 days in duration, have been proposed to manage prior histories of HCQ hypersensitivity.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Letters Source Type: research
Abstract Whether the presence or absence of antiphospholipid antibodies (aPL) in patients with lupus nephritis (LN) is associated with differences in clinical outcomes remains unclear. We reviewed LN patients at a single centre during 2000-2017, and compared the clinical features and long-term outcomes between patients who were seropositive or seronegative for aPL. aPL was detected in 53/149 (35.6%) patients with biopsy-proven LN, and anticardiolipin IgM, anticardiolipin IgG, anti-β2 glycoprotein I and lupus anticoagulant was detected in 18.8%, 18.1%, 10.7% and 8.1%, respectively. Follow-up was 155.8 &...
Source: Lupus - Category: Rheumatology Authors: Tags: Lupus Source Type: research
According to new research, women with SLE are at the highest risk for adverse pregnancy outcomes during a lupus flare. The data may enable clinicians to use risk stratification and tailored monitoring to counsel SLE patients who are pregnant or considering pregnancy. Researchers also found that maternal age, lupus nephritis and antiphospholipid antibodies may affect pregnancy outcomes...
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: Conditions SLE (Lupus) flare Flares Outcomes pregnancy pregnancy complications pregnant women Source Type: research
CONCLUSIONS: Multitarget therapy is an effective and safe intervention for inducing remission in lupus nephritis patients. PMID: 31580800 [PubMed - in process]
Source: J Pharm Pharm Sci - Category: Drugs & Pharmacology Authors: Tags: J Pharm Pharm Sci Source Type: research
More News: Allergy & Immunology | Glomeruli | Lupus | Nephritis